Citations (52)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Ashwani Sharma, Tarun Virmani, Anjali Sharma, Vaishnavi Chhabra, Girish Kumar, Kamla Pathak & Abdulsalam Alhalmi. (2022) Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance. Diabetes, Metabolic Syndrome and Obesity 15, pages 1845-1864.
Read now
Read now
Mingkai Zhang, Ling Zhu, Gangcheng Wu, Tongtong Liu, Xiguang Qi & Hui Zhang. (2022) Food-derived dipeptidyl peptidase IV inhibitory peptides: Production, identification, structure-activity relationship, and their potential role in glycemic regulation. Critical Reviews in Food Science and Nutrition 0:0, pages 1-23.
Read now
Read now
Caleb Acquah, Christian K. O. Dzuvor, Susan Tosh & Dominic Agyei. (2022) Anti-diabetic effects of bioactive peptides: recent advances and clinical implications. Critical Reviews in Food Science and Nutrition 62:8, pages 2158-2171.
Read now
Read now
Theodosios D. Filippatos, Angelos Liontos, Ioanna Papakitsou & Moses S. Elisaf. (2019) SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses. Postgraduate Medicine 131:2, pages 82-88.
Read now
Read now
Christos V. Rizos, Theodosios D. Filippatos & Moses S. Elisaf. (2018) Pharmacokinetic drug evaluation of empagliflozin plus linagliptin for the treatment of type 2 diabetes. Expert Opinion on Drug Metabolism & Toxicology 14:1, pages 117-125.
Read now
Read now
Sebastian Filippas-Ntekouan, Theodosios D. Filippatos & Moses S. Elisaf. (2018) SGLT2 inhibitors: are they safe?. Postgraduate Medicine 130:1, pages 72-82.
Read now
Read now
Theodosios Filippatos, Eleftheria Tzavella, Christos Rizos, Moses Elisaf & George Liamis. (2017) Acid-base and electrolyte disorders associated with the use of antidiabetic drugs. Expert Opinion on Drug Safety 16:10, pages 1121-1132.
Read now
Read now
Vasilios Tsimihodimos, Theodosios D. Filippatos & Moses S. Elisaf. (2017) Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies. Expert Opinion on Drug Metabolism & Toxicology 13:4, pages 399-408.
Read now
Read now
Takashi Kadowaki, Fuyuhiko Marubayashi, Shoko Yokota, Makoto Katoh & Hiroaki Iijima. (2015) Safety and efficacy of teneligliptin in Japanese patients with type 2 diabetes mellitus: a pooled analysis of two Phase III clinical studies. Expert Opinion on Pharmacotherapy 16:7, pages 971-981.
Read now
Read now
Terry A Jacobson. (2014) Perspectives on a new prescription omega-3 fatty acid, icosapent ethyl, for hypertriglyceridemia. Clinical Lipidology 9:2, pages 149-161.
Read now
Read now
Articles from other publishers (42)
Nikunj N Dave, Janvi P Shah & Akruti S Khodakiya. (2023) Concise review on anti-diabetic agents: Traditional to modern. Current Trends in Pharmacy and Pharmaceutical Chemistry 5:4, pages 114-122.
Crossref
Crossref
Mingkai Zhang, Ling Zhu, Hui Zhang, Xingguo Wang, Gangcheng Wu & Xiguang Qi. (2023) Transepithelial Transport of the Bifunctional Peptide IPYWTY Indirectly Induced Insulin Release Mediated by Active GLP-1. Journal of Agricultural and Food Chemistry 71:34, pages 12749-12756.
Crossref
Crossref
Seung Min Chung, Jun Sung Moon, Jun Hwa Hong, In‐Chang Hwang & Soo Lim. (2023)
Comparison of the effects of gemigliptin versus glimepiride on cardiac function in patients with type 2 diabetes uncontrolled with metformin: The
gemi‐heart
study
. Diabetes, Obesity and Metabolism 25:8, pages 2181-2190.
Crossref
Crossref
Hong-Hong Ma, Jing Zhang, Ci-Qin Li & Li-Wei Zou. (2023) Discovery of anthraquinones as DPP-IV inhibitors: Structure-activity relationships and inhibitory mechanism. Fitoterapia 168, pages 105549.
Crossref
Crossref
Eiji Kutoh, Alexandra N. Kuto, Midori Akiyama, Eri Ozawa & Rumi Kurihara. (2023) Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid. European Journal of Clinical Pharmacology 79:7, pages 947-959.
Crossref
Crossref
Yosuke Nakagawa, Masao Toyoda, Nobumichi Saito, Noriko Kaneyama, Tomomichi Shimizu, Tomotaka Mabuchi & Masafumi Fukagawa. (2023) Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center. Internal Medicine 62:12, pages 1715-1722.
Crossref
Crossref
Sae Im Jeong, Yun Kim, Jae Jin Nah, Wan Huh, In‐Jin Jang, Jun Gi Hwang & SeungHwan Lee. (2023) Pharmacokinetic and pharmacodynamic interaction of DWP16001, a sodium–glucose cotransporter 2 inhibitor, with gemigliptin and metformin in healthy adults. British Journal of Clinical Pharmacology 89:6, pages 1780-1788.
Crossref
Crossref
Bhawna Puri, Sunita Meena, Sathish Kumar M H, Prashant Ashok Shelke, Latha Sabikhi & Ashutosh. (2023) Encapsulation and Assessment of Antidiabetic Potential of α-Lactalbumin-Derived Hydrolysates. Journal of Agricultural and Food Chemistry 71:14, pages 5547-5553.
Crossref
Crossref
Eugenia Piragine, Davide Petri, Alma Martelli, Vincenzo Calderone & Ersilia Lucenteforte. (2023) Adherence to Oral Antidiabetic Drugs in Patients with Type 2 Diabetes: Systematic Review and Meta-Analysis. Journal of Clinical Medicine 12:5, pages 1981.
Crossref
Crossref
Toru Ogura & Chihiro Shiraishi. (2023) Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System. Clinical Drug Investigation 43:2, pages 129-140.
Crossref
Crossref
Federica Ferrari, Antonio Moretti & Roberto Federico Villa. (2022) Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives. Pharmacology & Therapeutics 239, pages 108277.
Crossref
Crossref
Mingkai Zhang, Ling Zhu, Gangcheng Wu, Tongtong Liu, Xiguang Qi & Hui Zhang. (2022)
Rapid Screening of Novel Dipeptidyl Peptidase-4 Inhibitory Peptides from Pea (
Pisum sativum L.
) Protein Using Peptidomics and Molecular Docking
. Journal of Agricultural and Food Chemistry 70:33, pages 10221-10228.
Crossref
Crossref
Alba Miguéns-Gómez, Àngela Casanova-Martí, M. Teresa Blay, Ximena Terra, Raúl Beltrán-Debón, Esther Rodríguez-Gallego, Anna Ardévol & Montserrat Pinent. (2021) Glucagon-like peptide-1 regulation by food proteins and protein hydrolysates. Nutrition Research Reviews 34:2, pages 259-275.
Crossref
Crossref
Hojin Oh, Hai Duc Nguyen, In Mo Yoon, Byung-Ryong Ahn & Min-Sun Kim. (2021) Antidiabetic effect of gemigliptin: a systematic review and meta-analysis of randomized controlled trials with Bayesian inference through a quality management system. Scientific Reports 11:1.
Crossref
Crossref
Hojin Oh, Hai Duc Nguyen, In Mo Yoon & Min-Sun Kim. (2021) Efficacy and Tolerability of Evogliptin in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis with Bayesian Inference Through a Quality-management System. Clinical Therapeutics 43:8, pages 1336-1355.
Crossref
Crossref
Chin-Ying Ray, Victor Chien-Chia Wu, Chun-Li Wang, Hui-Tzu Tu, Yu-Tung Huang, Chang-Fu Kuo & Shang-Hung Chang. (2021) Hypoglycemia Associated With Drug–Drug Interactions in Patients With Type 2 Diabetes Mellitus Using Dipeptidylpeptidase-4 Inhibitors. Frontiers in Pharmacology 12.
Crossref
Crossref
Omnia Azmy Nabeh, Magdy Ishak Attallah & Nawal El‐Sayed El‐Gawhary. (2020) The pivotal relation between glucagon‐like peptides, NFκB and inflammatory bowel disease. Clinical and Experimental Pharmacology and Physiology 47:10, pages 1641-1648.
Crossref
Crossref
Yuliet, Elin Y. Sukandar & I.K. Adnyana. (2020) Active Subfractions, Phytochemical Constituents, Dipeptidyl Peptidase-IV Inhibitory Activity and Antioxidant of Leaf Extract from Hibiscus surattensis L.. The Natural Products Journal 10:4, pages 400-410.
Crossref
Crossref
Ágnes Kinyó. 2020. Cellular Metabolism and Related Disorders. Cellular Metabolism and Related Disorders.
Analía Verónica Yamaguchi, Pablo René Costanzo, Verónica Andrea Peuchot & Pablo Knoblovits. (2019) Testosterone Replacement Therapy and the Risk of Hypoglycemia. Case Reports in Endocrinology 2019, pages 1-5.
Crossref
Crossref
Nordin MJ Hanssen & Karin AM Jandeleit-Dahm. (2019) Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?. Diabetes and Vascular Disease Research 16:4, pages 303-309.
Crossref
Crossref
Naina Mohamed Pakkir Maideen. (2019) Drug interactions of dipeptidyl peptidase 4 inhibitors involving CYP enzymes and P-gp efflux pump. World Journal of Meta-Analysis 7:4, pages 156-161.
Crossref
Crossref
Yohei Kawaguchi, Risa Shimauchi, Nobuhiro Nishibori, Kiyohito Kawashima, So Oshitani, Atsushi Fujiya, Taiga Shibata, Norimi Ohashi, Kentaro Izumi, Wataru Nishie, Hiroshi Shimizu, Hiroshi Arima & Hiroshi Sobajima. (2018) Dipeptidyl peptidase‐4 inhibitors‐associated bullous pemphigoid: A retrospective study of 168 pemphigoid and 9,304 diabetes mellitus patients. Journal of Diabetes Investigation 10:2, pages 392-398.
Crossref
Crossref
Isabelle M. E. Lacroix, Irene Dávalos Terán, Vincenzo Fogliano & Harry J. Wichers. (2018)
Investigation into the potential of commercially available lesser mealworm (
A. diaperinus
) protein to serve as sources of peptides with DPP‐IV inhibitory activity
. International Journal of Food Science & Technology 54:3, pages 696-704.
Crossref
Crossref
Rui Liu, Jianming Cheng & Hao Wu. (2019) Discovery of Food-Derived Dipeptidyl Peptidase IV Inhibitory Peptides: A Review. International Journal of Molecular Sciences 20:3, pages 463.
Crossref
Crossref
Xiaoxuan Li, Xuefei Huang, Chongfei Bai, Dalian Qin, Shousong Cao, Qibing Mei, Yun Ye & Jianming Wu. (2018) Efficacy and Safety of Teneligliptin in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Pharmacology 9.
Crossref
Crossref
Gulmira Turdu, Hongwei Gao, Yingying Jiang & Madina Kabas. (2018) Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review. Future Medicinal Chemistry 10:10, pages 1229-1239.
Crossref
Crossref
Christoph Reichetzeder, Karoline von Websky, Oleg Tsuprykov, Azadeh Mohagheghi Samarin, Luise Gabriele Falke, Sulistyo Emantoko Dwi Putra, Ahmed Abdallah Hasan, Viktoriia Antonenko, Caterina Curato, Jörg Rippmann, Thomas Klein & Berthold Hocher. (2017) Head‐to‐head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury. British Journal of Pharmacology 174:14, pages 2273-2286.
Crossref
Crossref
Ankit Gupta, Herbert F. Jelinek & Hayder Al-Aubaidy. (2017) Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 11:3, pages 225-230.
Crossref
Crossref
Isabelle M. E. Lacroix, Xiu-Min Chen, David D. Kitts & Eunice C. Y. Li-Chan. (2017) Investigation into the bioavailability of milk protein-derived peptides with dipeptidyl-peptidase IV inhibitory activity using Caco-2 cell monolayers. Food & Function 8:2, pages 701-709.
Crossref
Crossref
Nobumasa Ohara, Masanori Kaneko, Kazuhiro Sato, Ryoko Maruyama, Tomoyasu Furukawa, Junta Tanaka, Kenzo Kaneko & Kyuzi Kamoi. (2016) Vildagliptin-induced acute lung injury: a case report. Journal of Medical Case Reports 10:1.
Crossref
Crossref
Pablo Yang, Verónica Ojeda Heredia, Dante M. Beltramo & Néstor W. Soria. (2016) Pharmacogenetics and personalized treatment of type 2 diabetes mellitus. International Journal of Diabetes in Developing Countries 36:4, pages 508-518.
Crossref
Crossref
Sung-Ho Kim, Eunsoo Jung, Min Kyung Yoon, O. Hwan Kwon, Dal-Mi Hwang, Dong-Wook Kim, Junghyun Kim, Sun-Mee Lee & Hyeon Joo Yim. (2016) Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo. European Journal of Pharmacology 788, pages 54-64.
Crossref
Crossref
Isabelle M.E. Lacroix & Eunice C.Y. Li-Chan. (2016) Food-derived dipeptidyl-peptidase IV inhibitors as a potential approach for glycemic regulation – Current knowledge and future research considerations. Trends in Food Science & Technology 54, pages 1-16.
Crossref
Crossref
Marcus May & Christoph Schindler. (2016) Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic Advances in Endocrinology and Metabolism 7:2, pages 69-83.
Crossref
Crossref
Isabelle M.E. Lacroix, Guangtao Meng, Imelda W.Y. Cheung & Eunice C.Y. Li-Chan. (2016) Do whey protein-derived peptides have dual dipeptidyl-peptidase IV and angiotensin I-converting enzyme inhibitory activities?. Journal of Functional Foods 21, pages 87-96.
Crossref
Crossref
Sen Shi, Keizo Kanasaki & Daisuke Koya. (2016) Linagliptin but not Sitagliptin inhibited transforming growth factor-β2-induced endothelial DPP-4 activity and the endothelial-mesenchymal transition. Biochemical and Biophysical Research Communications 471:1, pages 184-190.
Crossref
Crossref
Sung-Ho KimJung-Hwa YooWoo Je LeeCheol-Young Park. (2016) Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes Mellitus. Diabetes & Metabolism Journal 40:5, pages 339.
Crossref
Crossref
Enrique Z. Fisman & Alexander Tenenbaum. (2015) Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovascular Diabetology 14:1.
Crossref
Crossref
Isabelle M.E. Lacroix & Eunice C.Y. Li-Chan. (2015) Comparison of the susceptibility of porcine and human dipeptidyl-peptidase IV to inhibition by protein-derived peptides. Peptides 69, pages 19-25.
Crossref
Crossref
M. K. Kim, E.‐J. Rhee, K. A. Han, A. C. Woo, M.‐K. Lee, B. J. Ku, C. H. Chung, K.‐A. Kim, H. W. Lee, I. B. Park, J. Y. Park, H. C. Chul Jang, K. S. Park, W. I. Jang & B. Y. Cha. (2015)
Efficacy and safety of teneligliptin, a dipeptidyl peptidase‐4 inhibitor, combined with metformin in
K
orean patients with type 2 diabetes mellitus: a 16‐week, randomized, double‐blind, placebo‐controlled phase
III
trial
. Diabetes, Obesity and Metabolism 17:3, pages 309-312.
Crossref
Crossref
Theodosios D. Filippatos, Evangelos N. Liberopoulos & Moses S. Elisaf. (2014) Dapagliflozin in patients with type 2 diabetes mellitus. Therapeutic Advances in Endocrinology and Metabolism 6:1, pages 29-41.
Crossref
Crossref